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Abstract  
 
Background 
Tuberculosis (TB) is known as a disease of the poor. Despite TB diagnosis and care usually being 
offered for free, TB patients can still face substantial costs, especially in the context of multi-drug 
resistance (MDR). The End TB Strategy calls for zero TB-affected families incurring “catastrophic” 
costs due to TB by 2025. 
 
Objectives 
This paper examines the level and composition of costs incurred by TB-affected households during 
care seeking and treatment, by MDR status; examines affordability of TB care using catastrophic and 
impoverishment measures; and describes coping strategies used by TB-affected households to pay 
for TB care. 
 
Methods 
A nationally representative survey of TB patients at public health facilities across Ghana.  
 
Results 
We enrolled 691 patients (66 MDR). The median expenditure for non-MDR TB was US$429.6 during 
treatment, compared to US$659.0 for MDR patients (p-value=0.001). 
 
Catastrophic costs affected 64.1% of patients. MDR patients were pushed significantly further over 
the threshold for catastrophic payments than DS patients. Payments for TB care led to a significant 
increase in the proportion of households in the study sample that live below the poverty line at the 
time of survey compared to pre-TB diagnosis. Over half of patients undertook coping strategies. 
 
Conclusion  
TB patients in Ghana incur substantial costs, despite free diagnosis and treatment. High rates of 
catastrophic costs and coping strategies in both non-MDR and MDR patients show that new policies 
are urgently needed to ensure TB care is actually affordable for TB patients.   
 
  3 
Introduction and background 1 
 2 
Much has been achieved in tuberculosis (TB) control since the World Health Organization (WHO) 3 
declared it a global emergency in the mid-nineties (1). Yet TB, with an estimated 10.4 million new 4 
cases and 1.7 million TB-related deaths globally in 2016, is now the leading cause of mortality from a 5 
single infection (2).   6 
 7 
TB also represents an equity challenge. While TB is not solely a disease of the poor, poverty and 8 
inequity fuel the TB epidemic (3, 4). Poverty has been found to increase the risk of acquiring TB 9 
infection and developing the disease through more proximal risk factors such as malnutrition and 10 
overcrowded living conditions (5-7).  Poverty also limits access to care for TB patients, particularly in 11 
low- and middle-income countries (LMICs), where health care financing is characterised by a heavy 12 
reliance on out-of-pocket (OOP) payments and the limited coverage of prepayment mechanisms 13 
(e.g. taxation, health insurance)(8). Even when TB diagnosis and treatment are provided free of 14 
charge, TB patients often incur transport, accommodation and time costs associated with care 15 
seeking (9). Costs can be a deterrent to accessing diagnosis and care in the first place for those with 16 
constrained incomes (10), and where patients do seek care, costs reduce available income making 17 
the patient, and their household more vulnerable to financial hardship (11). Where households 18 
struggle to afford care, TB patients will be less likely to adhere to treatment and may fail to 19 
complete it (12), thus leading to increased TB transmission in the household and community, as well 20 
as exacerbating individual morbidity and mortality (13).   Affordability is a particular concern for 21 
treatment of multi-drug resistant (MDR)-TB which often lasts for more than 18 months (14, 15). 22 
 23 
Recognising this challenge, the WHO’s End TB Strategy for the 2015-2035 era includes a target of 24 
preventing any TB patient from incurring “catastrophic” costs due to TB, or ensuring that costs do 25 
not exceed 20% of annual household income (16, 17).  26 
 27 
However, while there have been previous assessments of TB patient costs in LMICs (18) (including in 28 
Ghana, (19)), most studies did not report costs as a proportion of income, nor did they measure 29 
affordability of TB care (14).  To enhance the evidence base on the costs and affordability of TB care, 30 
WHO developed a survey tool to enable rigorous measurement of TB patient costs and their share of 31 
household income (20). 32 
 33 
Here we report findings from a nationwide representative sample of TB patients in Ghana, the first 34 
study to use this survey tool in sub-Saharan Africa (SSA). This paper examines the level and 35 
composition of costs incurred by TB-affected households during care seeking and treatment, by 36 
MDR status; examines affordability of TB care using catastrophic and impoverishment measures; 37 
and describes coping strategies used by TB-affected households to pay for TB care. 38 
 39 
Methods 40 
 41 
Study setting 42 
Despite positive economic growth over the past two decades and consequent reduction in poverty 43 
levels (21), 25.2% of people in Ghana still live below $1.90/day and economic and health inequalities 44 
persist and have worsened (22). 45 
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 46 
TB incidence in Ghana was estimated at about 160 per 100,000 population in 2016 (2). A prevalence 47 
survey was conducted in 2013, which also highlighted barriers to accessing and adhering to TB care. 48 
Diagnostics and treatment for TB are officially offered free of charge by public providers to all 49 
presumptive patients and individuals diagnosed with TB disease, with the exception of chest 50 
radiography (23).  51 
 52 
Data collection 53 
In late 2016, we conducted a nationally representative survey with random cluster sampling among 54 
TB patients at health facilities within the National TB Programme network, using an adapted and 55 
expanded version of the WHO patient cost tool. Twenty-five districts (clusters) across Ghana were 56 
sampled using a probability proportional to size approach, where each district’s chance of being 57 
selected was relative to the number of TB patients notified in that district in 2015. 58 
 59 
Eligibility for the study was restricted to TB patients registered for treatment, attending a health 60 
facility within a sampled cluster, who had received at least two weeks of intensive or continuation 61 
phase treatment, and who consented to the study.  In total, 734 individuals were interviewed; of 62 
these, 691 (94%) were eligible and consented to take part in the study. We collected information on 63 
TB-related costs incurred by respondents, as well as on their clinical, demographic, and socio-64 
economic characteristics.  65 
 66 
Costs incurred by TB affected households 67 
The survey collected data on direct medical (consultation fees, drugs, laboratory tests) and non-68 
medical (e.g. transport and food) costs, and indirect costs (the time lost by a patient seeking and 69 
receiving care), up to the time of interview.  To value time, we employed the output-related 70 
approach, by which the value of time is defined as the difference in household annual income pre 71 
and post-TB diagnosis (24). To minimise recall bias, data were collected only for the treatment phase 72 
the patient was in at the time of interview (i.e. intensive or continuation phase). 73 
 74 
To estimate patient costs for the entire TB episode, including costs for all phases of treatment, we 75 
extrapolated costs based on data from patients in other phases of illness. We used the approach 76 
recommended by WHO, whereby missing cost data were replaced by the median cost of the phase 77 
of illness among those in that phase with available data (20).  78 
 79 
 80 
Affordability of TB care 81 
We computed four summary metrics of affordability of health care: i) the catastrophic payment 82 
headcount, ii) catastrophic payment gap), iii) impoverishment incidence and iv) poverty gap (25).  83 
 84 
For the catastrophic payment headcount ratio, consistent with the approach adopted by WHO for 85 
the “zero TB-affected families facing catastrophic costs due to TB” indicator, costs were defined as 86 
“catastrophic” if a household incurred total TB-related costs (direct and indirect) exceeding 20% of 87 
their pre-disease annual household income (20). The catastrophic payment gap represents the 88 
amount by which households exceed this threshold (26). 89 
 90 
 91 
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The impoverishment incidence measures the increase in poverty resulting from households incurring 92 
costs for TB care. The World Bank US$ 1.90/day international poverty line is used in this study (27). 93 
The poverty gap is the short-fall from this poverty line (28). 94 
 95 
Income was measured as self-reported individual and household income where available (n=553). If 96 
missing, income estimates were based on self-reported household assets (e.g. composition of floor 97 
or ownership of a mobile phone) using a regression-based approach  (n=134)(20) (Annex), or 98 
minimum reported income where only one asset was reported (n=4).  Metrics were computed using 99 
the best available measure of income for each household.  100 
 101 
We used a Pen’s parade chart to plot two income distributions (gross income and income net of 102 
payments for TB) using a cumulative proportion of individuals ranked according to their gross 103 
household income, to show the potential decrease in household welfare due to payments for TB 104 
care and consequent reduction in household income (29). 105 
 106 
Coping mechanisms 107 
We also computed a complementary metric (“coping”) if households undertook any of the following: 108 
borrowing (having taken a loan), selling household items or assets (e.g. livestock), and use of savings. 109 
 110 
Data analyses 111 
We report descriptive analysis of the level (median and interquartile range, IQR) and composition of 112 
costs. We used median values of costs and time as opposed to means due to the skewed 113 
distributions of both costs and time spent seeking care. Given the higher costs reported in previous 114 
studies for MDR-TB versus drug susceptible (DS) patients, results are presented by MDR status (14, 115 
15). 116 
 117 
Comparisons between costs for DS and MDR patients were made using chi-square and Wilcoxon 118 
Rank Sum test. All analyses were run in Stata v13.0 (StataCorp, College Station, TX). Costs were 119 
converted to United States Dollars (US$) using the average annual exchange rate during study 120 
enrolment of US$1=4.15 Ghanaian cedis (oanda.com). 121 
 122 
Sensitivity analyses 123 
For estimating missing costs, we employed a regression-based approach, by estimating costs for that 124 
patient and treatment phase using a set of variables conceptually linked to incurring costs (sex, age, 125 
occupation, rural/urban residence). We also varied the 20% threshold for catastrophic costs to see 126 
how this would affect the proportion of households deemed as facing catastrophic costs. Additional 127 
thresholds we considered were 10%, 40% and 50% that have been previously used in the healthcare 128 
literature (30-33). The catastrophic payment headcount was also computed using consumption 129 
expenditure instead of income as a robustness check (34), because in settings where employment is 130 
mainly outside the formal sector, consumption expenditure is often believed to be a more valid 131 
measure than income (35-37). Finally, we also looked at how taking into account only direct costs 132 
would impact on the proportion of households confronting financial catastrophe. 133 
 134 
Ethics 135 
The study was approved by the research ethics committees of the London School of Hygiene and 136 
Tropical Medicine (REF:11240) and Ghana Health Service (GHS-ERC 14/06/16). 137 
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Findings 138 
Half the sampled patients had a secondary level education and were non-salaried employees (Table 139 
1). Three-quarters of respondents lived in an urban setting. Sixty-six (9.6%) respondents were being 140 
treated for MDR-TB at the time of survey, and about a tenth had already been treated for TB in the 141 
past (Table 1). Ninety respondents were new cases in their intensive phase of treatment and 142 
reported on average a delay of four weeks between experiencing symptoms and diagnosis. The 143 
characteristics of DS and MDR patients did not differ significantly overall, although DS patients were 144 
more likely to be newly diagnosed and have larger household size. 145 
 146 
Table 1: Descriptive statistics and selected socio-demographic and economic characteristics of the 147 
study population, by MDR status and overall.  148 
 
        
Characteristic 
DS-TB MDR-TB 
p-value 
All  
N= 625 N= 66 N= 691 
Sex, N (%)         
  Male  423 (67.7%)  42 (63.6%) 
0.51 
 465 (67.3%) 
  Female  202 32.3%)  24 (36.4%)  226 (32.7%) 
Age in years, Median  [IQR]  41 [29-52]  43 [29-50] 0.88  41 [29-52) 
Phase, N (%)         
   Intensive  210 (33.6%)  22 (33.3%) 
0.10 
 232 (33.6%) 
   Continuation  415 (66.4%)  44 (66.7%)  459 (66.4%) 
Recorded HIV Status, N (%)         
  Positive  121 (19.4%)  8 (12.1%) 
0.78 
 129 (18.7%) 
  Negative  431 (69.0%)  32 (48.5%)  463 (67.0%) 
  Unknown  73 (11.7%)  26 (39.4%)  99 (14.3%) 
Retreatment  status, N (%)         
  New  560 (89.6%)  55 (83.3%) 
0.08 
 615 (89%) 
  Retreatment/Relapse  65 (10.4%)  11 (16.7%)  76 (11%) 
Diagnosis delay (weeks ), Median (SD) 4 (16.2) 6 (12.9)   4 (15.9) 
  N (%) 80 (44.2%) 10 (52.6%) 0.48 90 (45%) 
Patient’s education status, N (%) 623 66   689 
No education  125 (20.1) 11 (16.7) 
0.24 
136 (19.7)  
   Primary school 122 (19.6) 8 (12.1) 130 (18.9) 
   Secondary school / High school  350 (56.2)  42 (63.6)  392 (56.9) 
   University and higher  26 (4.2)  5 (7.6)  31 (4.5) 
Occupation pre-disease (by main categories), N (%) 525 59   691 
Salaried 70 (13.3) 9 (15.4) 
0.16 
79 (13.5) 
Not salaried 269 (51.2) 36 (61.0) 305 (52.2) 
Not employed / In school 186 (35.4) 14 (23.7) 200 (34.3) 
Place of residence, N (%) 621 66   687 
   Urban 444 (71.5) 47 (71.2) 
0.96 
491 (71.5) 
   Rural 177 (28.5) 19 (28.8) 196 (28.5) 
Household size, Median [IQR] 6 [4;11] 4 [3;9] 0.01 6 [4;11] 
  7 
Monthly household income in US$ [IQR]✝ 144.6 [79.5-241.0] 
154.7 [96.4-
241.0] 0.34 144.6 [84.3-241.0] 
✝Pre-TB diagnosis         
 149 
Costs incurred by TB affected households 150 
The median (IQR) costs that TB patients incurred as a result of TB was US$ 455 (159.2-1059.2).  151 
MDR-TB patients incurred significantly higher costs than DS patients: the median expenditure for DS-152 
TB patients was US$ 429.6 (154.0-981.2), and for MDR-TB patients was US$ 659.0 (93.2-1680.3) (p-153 
value=0.001).   154 
 155 
Costs after diagnosis were most significant at 93% of total.  This was largely driven by non-medical 156 
costs, notably income loss (42% for DS and 49% for MDR patients). Median lost income was US$ 0.0 157 
(0.0-195.2) for DS patients and US$ 0.0 (0.0-216.9) for MDR-TB (p-value=0.38). The median 158 
percentage of household income lost due to TB was US$ 0.0% (0.0%-14.6%) for DS and US$ 0.0% 159 
(0.0%-14.2%) for MDR-TB patients (p-value=0.43). 160 
 161 
While there was no difference in median costs between DS and MDR before diagnosis, the median 162 
costs after diagnosis were almost three times greater for the MDR group (p-value<0.0001) (US$ 163 
1276 versus US$ 481), due to higher levels of non-medical costs among the MDR group 164 
(supplementary Table A1). Food and/or nutritional supplements outside the patient’s normal diet 165 
were the largest contributors to non-medical expenses and these were significantly higher for MDR 166 
than for DS patients (36% vs. 21% of total costs) (Figure 1).  167 
 168 
Figure 1: Composition of costs pre and post-TB diagnosis, by MDR status. 169 
 170 
a)   DS-TB     b) MDR-TB 171 
 172 
 173 
Affordability of TB care  174 
The median percentage of household income spent on TB was 32.3% (IQR: 11.7%-61.2%), which was 175 
significantly higher for MDR compared to DS patients (48.8% versus 31.3%, p-value=0.0016). 176 
 177 
The proportion of patients incurring catastrophic costs at a 20% threshold of annual household 178 
income was 64.1% (443/691) (95% confidence interval: 60.5%-67.6%) (catastrophic payment 179 
headcount ratio). This ratio was estimated at 77.3% for MDR patients versus 63.2% for DS individuals 180 
– a difference which was not statistically significant (p-value=0.125). 181 
8%
1%
22%
6% 0%
21%
42%
Medical	(before	diagnosis) Non-medical	(before	diagnosis)
Medical	(after	diagnosis) Non-medical:	Travel	(after	diagnosis)
Non-medical:	Accomodation	(after	diagnosis) Non-medical:	Food	(after	diagnosis)
Income	loss
Total	costs	(median):	US$	429.6	 4% 1%
6%
4%
0%
36%
49%
Medical	(before	diagnosis) Non-medical	(before	diagnosis)
Medical	(after	diagnosis) Non-medical:	Travel	(after	diagnosis)
Non-medical:	Accomodation	(after	diagnosis) Non-medical:	Food	(after	diagnosis)
Income	loss
Total	costs	(median):	US$	650.0	
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 182 
For the catastrophic payment gap, patients overshot the 20% threshold by an average of 39.2 183 
percentage points overall. This indicator was significantly higher for MDR patients (59.2%) than for 184 
DS patients (37.1%) (p-value=0.005).  185 
 186 
Payments for TB care led to a significant increase in the proportion of households in the study 187 
sample that live below the poverty line (PPP US$ 1.90/day) (p-value<0.001), from 45.6% before TB 188 
diagnosis to 59.8% at the time of the survey (poverty headcount ratio).  There was no statistical 189 
difference between the levels of poverty pre-diagnosis nor of the proportions shifted below the 190 
poverty line between MDR and DS patients.  191 
 192 
The poverty gap, the short-fall from the international poverty line, increased from 60.8% (61.8% for 193 
DS and 50.7% for MDR, p-value=0.012) to 67.0% at the time of survey (68.4% for DS and 56.0% for 194 
MDR, p-value=0.026), a relative increment of 10%, which did not significantly differ by MDR status. 195 
 196 
The “paint drips” in the Pen’s chart suggest that payments for TB care led to a decrease in household 197 
income and therefore to a decrease in household welfare. It is primarily households in the middle 198 
and lower half of the income distribution that are pushed below the poverty line or further into 199 
poverty by payments for TB (Figure 2). 200 
 201 
Figure 2: Pen’s parade of household income gross and net of payments for TB (red line represents 202 
the poverty line at US$ 2.02 PPP (2015)*). 203 
 204 
 205 
 206 
* US$ 2.02 PPP (2015)=US$ 1.90 PPP (2011), which is equal to 2.79 Ghanaian cedis (December 2016, 207 
oanda.com). 208 
 209 
Coping mechanisms 210 
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Over half (51.5%) of patients were unable to pay for TB-treatment from existing income alone, and 211 
had to rely on savings, borrowing or selling assets (collectively termed: coping strategies) to pay for 212 
TB-related care (Table 2). This did not significantly differ by MDR status (p=0.4). 213 
 214 
Table 2: Reported dissaving mechanisms by MDR status. 215 
 216 
Coping strategies DS, % (N) MDR, % (N) All, % (N) 
Loan 
27.0 (169/625) 30.3 (20/66) 
27.4 
(189/691) 
Use of savings 
29.4 (184/625) 16.7 (11/66) 
28.2 
(195/691) 
Sale of assets 
10.7 (67/625) 15.2 (10/66) 
11.1 
(77/691) 
Any of the three above 
52.0 (325/625) 47.0 (31/66) 
51.5 
(356/691) 
 217 
  218 
Productivity loss 219 
Nearly three-quarters (73.7%) of patients lost days of work due to TB diagnosis and treatment, and 220 
this proportion was significantly highger for DS patients (92.0%) than for DS patients (8.15%) 221 
(p<0.008). The median number of working days of income lost was 54 (IQR: 0-150), and this was 222 
significantly higher for DS patients (56 days; IQR: 1-150) than for MDR patients (24.5 days: IQR: 0-90) 223 
(p=0.008). The median number of days lost by patients in the formal sector was 30 (IQR: 0-120), 224 
versus 60 days (IQR: 14-150) for patients in the informal sector. More than forty percent (41.0%) of 225 
patients reported that they lost their job as a result of TB. This was not significantly different by MDR 226 
status (p=0.186). 227 
 228 
Sensitivity analyses 229 
Using the regression-based approach to impute costs instead of the median cost approach, the level 230 
of costs incurred decreased by 18.2%, leading to lower estimates of catastrophic costs which 231 
significantly differed by MDR status (53.1% for DS and MDR 72.7%; p-value=0.002) (supplementary 232 
Table A2 and A3).  233 
 234 
When we used annual household consumption expenditure instead of income, the proportion of 235 
households incurring catastrophic costs was fairly consistent (61.8%) and the difference between DS 236 
and MDR patients remained statistically insignificant (61.2% versus 67.7%, p-value=0.305). 237 
 238 
As the income threshold increases, the catastrophic payment headcount ratio decreases accordingly, 239 
but even at a 40% threshold of annual household income 42.3% of patients would be still considered 240 
to incur catastrophic costs (supplementary Figure 1A). This ratio was significantly different for DS 241 
and MDR patients (40.6% versus 57.6%, p-value=0.008). 242 
  243 
When we took into account only direct costs in the numerator, 49.1% of patients incurred financial 244 
catastrophe, and the difference between DS and MDR patients was significant (47.6% for DS and 245 
63.6% MDR, p-value=0.013). 246 
 247 
Discussion  248 
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Our findings show that despite policies of free TB care in the public sector in Ghana, TB patients lack 249 
financial protection, with two-thirds of TB-affected households facing financial catastrophe, an 250 
additional 14.2% pushed into poverty due to the disease, and half undertaking coping strategies to 251 
finance costs.  The increase in the poverty gap means that not only is the number of TB-affected 252 
households in Ghana that experience catastrophic health payments high, but these households (and 253 
especially MDR affected families) also substantially exceed this threshold.  254 
 255 
Median costs that TB patients incurred in Ghana are higher than what was found in the systematic 256 
review by Tanimura et al (US$ 379), and in a previous study conducted by Mauch et al in two regions 257 
of Ghana in 2009 (US$ 202)(14, 19). Although it is hard to directly compare our findings to those 258 
from these studies due to the different methodologies employed, it is possible to draw similar 259 
conclusions pointing to the financial catastrophe and impoverishment faced by TB patients in Ghana 260 
due to TB. 261 
 262 
The proportion of TB patients living below the poverty line is greater than in the general population 263 
(45.6% vs. 24.2%) (38). This means that TB patients are more vulnerable and policies that can 264 
effectively defray costs incurred by TB patients are warranted.  As direct medical expenditures only 265 
account for 18.2% of total costs, universal health coverage is unlikely to impact on the number of 266 
families facing catastrophic costs. Income loss and food and/or nutritional supplements are the 267 
largest cost components. This calls for social protection interventions aimed at income replacement 268 
or food assistance programmes, such as the provision of food packages, specifically targeting TB 269 
patients (39).  270 
 271 
Findings from our study clearly show that to address the devastating economic burden of TB care on 272 
TB-affected households, multi-sectoral actions are needed. Eliminating direct medical cost requires 273 
thorough review of TB service delivery including streamlined access to quality TB diagnostics and 274 
care. To mitigate direct non-medical costs and indirect costs, social support and protection measures 275 
need to be enhanced and integrated with TB care. As many patients lost their job as a result of TB, 276 
labour protection for TB patients needs to be endorsed and implemented effectively. 277 
 278 
Costs incurred pre-diagnosis only account for 7.0% of total costs. The difference in costs between DS 279 
and MDR lies primarily in post-diagnosis costs. This is consistent with other surveys that followed the 280 
WHO methodology (40), but considerably differs from the findings from the systematic review by 281 
Tanimura et al., where costs incurred before treatment initiation represented half of total costs. This 282 
is likely due to the fact that studies included in this review employed heterogeneous data collection 283 
methods (14). It can also be argued that TB programmes may now be able to link people to care 284 
earlier by, for example, further decentralising diagnostic facilities or implementing more systematic 285 
case finding activities. This would lead to lower pre-diagnosis costs. 286 
 287 
As in previous studies, we found that MDR patients face substantially higher costs than DS-TB which 288 
is driven by non-medical expenditures.  While there was no statistical difference in the proportion of 289 
patients incurring catastrophic expenditures by MDR status, MDR patients were pushed significantly 290 
further over the threshold for catastrophic payments than DS patients. To our knowledge, this is the 291 
first study to find this. However, when the numerator for catastrophic expenditures is limited to 292 
direct costs as is the case conventionally for financial protection measurement, the MDR patients 293 
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were more likely to incur catastrophic expenditures than DS patients. The impoverishing effects of 294 
the disease did not significantly differ by MDR status.  The long-term care of the disease makes this 295 
group particularly at risk of catastrophic costs and this requires special consideration in TB control 296 
programming. 297 
 298 
Further, though the evidence on the effects of costs on TB treatment outcomes remains scanty, it 299 
may be reasonable to assume that higher costs associated with seeking and adhering to treatment 300 
may lead to worse outcomes by reducing household resources available for food and worsening 301 
living conditions. Therefore, the importance of assessing costs may also be clinically relevant. 302 
 303 
Limitations 304 
This study has several limitations. Firstly, it only focused on Ghana, which has low HIV and MDR 305 
prevalence, hence our estimate of TB-related costs may be lower compared to other SSA settings 306 
with higher TB-HIV and MDR rates.  307 
 308 
Second, this survey was conducted in health facilities in the NTP network, in line with the WHO 309 
protocol; however, the 2013 prevalence survey found that 38.5% of patients in Ghana seek care at 310 
private facilities. As we do not know if these patients are wealthier or poorer than those in the 311 
general population(41), we cannot determine whether the exclusion of the private sector has led to 312 
overestimating or underestimating TB-related costs. 313 
 314 
In addition, the prevalence survey found little evidence to suggest strong geographical 315 
heterogeneity. If the TB epidemic is truly generalised, then districts with low notification rates can 316 
be a sign that cases are either not seeking care when needed, have limited access (perhaps 317 
geographically) to healthcare or are seeking care, but are being missed by the health system.  Our 318 
findings may underestimate costs because we overlooked the financial impact on individuals that 319 
forgo medical care because they cannot afford to pay (e.g. to reach the health facility). This is a 320 
limitation of the sampling methodology which tends to select districts with high notifications and, 321 
therefore, possibly with better off patients. 322 
 323 
This was a cross-sectional study. A major limitation to the estimation of costs incurred by patients is 324 
recall bias, i.e. patients not accurately remembering the amount of time or money they spent in 325 
seeking care for their TB diagnosis and treatment. We attempted to minimise recall bias by asking 326 
patients only about the treatment phase they were in, and extrapolating costs to the entire episode 327 
using two different approaches. While this assumes that every patient successfully completes 328 
treatment, it is difficult to determine how patients who fail and/or re-start treatment or die while 329 
being treated affect our estimates of costs. We found some sensitivity based on the regression-330 
based approach, but this did not affect the main findings and still meant that over half the 331 
respondents face financial catastrophe. This remained true when we considered only direct costs.  332 
 333 
Finally, this analysis only focuses on the one period consequences of TB, but the effects of coping 334 
mechanisms, and the impoverishing and catastrophic consequences of the disease for the household 335 
span well beyond the TB episode by reducing labour supply and productivity. 336 
 337 
 338 
 339 
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Conclusions 340 
Although TB diagnosis and treatment are provided free of charge, TB patients in Ghana incur 341 
substantial costs and lack financial protection. As non-medical and indirect costs account for the 342 
majority of these costs, free TB care is clearly not enough.  343 
 344 
High rates of catastrophic costs and coping in both non-MDR and MDR patients show that new 345 
policies beyond providing free TB care are urgently needed to offset non-medical and indirect costs, 346 
and ensure TB care is actually affordable for TB patients. It is therefore essential that countries 347 
undertaking TB patient cost surveys follow up on the survey findings by conducting, for example, 348 
national consultations with key stakeholders to discuss policy and practice implications, and 349 
effectively translate these findings into concrete action.350 
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Appendix  
 
1) Table A1: Summary of costs before and after diagnosis, by MDR status and overall.  
Cost component 
DS-TB (N=625) MDR-TB (N=66) All (N=691) 
Median IQR Median IQR Median IQR 
Costs before diagnosis 31.6 30.2-35.9 32.8 31.4-37.3 31.7 30.2-35.9 
Medical costs 26.7 26.7-26.7 27.7 27.7-27.7 26.7 26.7-26.7 
Non-medical costs  2.9 2.9-2.9  2.9 2.9-2.9 2.9 2.9-2.9 
Costs after diagnosis 481.7 220.1-1032.8 1276.3 442.7-2456.2 519.3 232.3-1161.2 
Medical costs 74 55.8-77.0 40.7 8.3-101.3 70.0 55.8-77.5 
Non-medical costs 140.6 31.0-427.6 427.6 112.1-1061.3 149.3 32.3-524.0 
Travel   18.3  8.1-49.2 27.1 8.1-131.2 18.3 8.1-51.3 
Accommodation 0.0 0.0-0.0 0.0 0.0-0.0 0.0 0.0-0.0 
Food/nutritional 
supplements 
68.4 9.7-327.5 227.9 18.9-708.4 
78.2 10.1-360.1 
Caregiver's time 0.0 0.0-0.74 0.0 0.0-20.5 0.0 0.0-0.56 
Income loss 0.0 0.0-195.2 0.0 0.0-216.9 87.3 0.0-506.0 
Total costs 429.6 154.0-981.2 659 393.2-1680.3 455.0 159.2-1059.2 
 
 
2) Table A2: Sensitivity analysis (regression-based method): Summary of costs before and after 
diagnosis, by MDR status and overall.  
 
Cost component 
DS-TB (N=625) MDR-TB (N=66) All (N=691) 
Median IQR Median IQR Median IQR 
Costs before 
diagnosis 
19.2 17.9-27.6 12 10.4-17.2 
12.4 
10.5-19.1 
Medical costs 15.7 15.7-15.7 8.4 8.4-8.4 8.4 8.4-8.4 
Non-medical costs 1.2 1.2-1.2 1.2 1.2-1.2 1.2 1.2-1.2 
Costs after diagnosis 404.6 150.9-958.8 1250.8 431.9-2405.9 454.1 163.2-1083.5 
Medical costs 0.0 0.0-14.4 0.0 0.0-86.7 0.0 0.0-20-6 
Non-medical costs 129.5 19.3-484.0 425.2 109.6-1051.7 139.7 21.7-516.0 
Total costs 341.9 67.5-893.1 634.5 354.2-1630.0 372.7 73.4-971.4 
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3) Table A3: Sensitivity analysis (regression-based method): Catastrophic payments due to TB at the 
20% threshold, by MDR status and living standard measure employed.  
 
Living standard measure 
employed 
Households facing catastrophic costs 
DS, % (N) MDR, % (N) All, % (N) 
Income 53.1 (332/625) 72.7 (48/66) 55.0 (380/691) 
Consumption 
expenditure 49.8% (296/595) 66.2% (43/65) 51.4 (339/660) 
 
 
4) Figure A1: Sensitivity analysis of catastrophic costs threshold.  
 
 
 
 
5) Prediction of household annual income based on asset ownership/dwelling characteristics. 
 
We selected all of the asset variables from the 2014 Ghana Demographic and Health Survey 
dataset(42), which measures both asset ownership and household income. Variables included 
household characteristics (e.g. the type of flooring material, availability of electricity, the number of 
rooms used for sleeping, place for cooking, type of cooking fuel), and household possessions (e.g. 
household effects such as radio, colour television, mobile/non-mobile telephone, refrigerator; 
means of transport, including bicycle, animal drawn cart, car/truck, boat with a motor; ownership of 
agricultural land and farm animals). We then employed a multi-variable linear regression model to 
predict household income. We selected those variables that were most strongly associated with 
income by looking at those with the smallest p-values or largest test statistics from the resulting 
regression. This list of selected assets was included in the survey questionnaire. 
 
This method may be useful in countries like Ghana with a large informal sector and where a 
validated set of questions on asset ownership or dwelling characteristics exists, as recommended in 
the WHO’s “Tuberculosis Patient Cost Surveys: A Handbook”(20). 
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